A Little Of Our Story
About Us
Lifestyle diseases, caused by poor diet and physical inactivity among others, are rising worldwide. Each year 70% of all deaths globally – 40 million – are attributed to lifestyle diseases such as obesity, type 2 diabetes and heart disease.
Sigrid is a purpose-driven, consumer focused healthtech company envisioning a world where no one falls sick with chronic lifestyle diseases.
A Little Of Our Story
About Us
Lifestyle diseases, caused by poor diet and physical inactivity among others, are rising worldwide. Each year 70% of all deaths globally – 40 million – are attributed to lifestyle diseases such as obesity, type 2 diabetes and heart disease.
Sigrid is a purpose-driven, consumer focused healthtech company envisioning a world where no one falls sick with chronic lifestyle diseases.
A Breakthrough in Prediabetes Innovation
SiPore21® is a breakthrough medical device for the safe reduction of blood sugar levels in people at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics. The device is orally consumed, and it is a tasty, easy-to-use gel. Upon its approval, SiPore21® will be the first treatment available for prediabetes, with the potential to prevent type 2 diabetes.
SiPore21® is Sigrid Therapeutics’ lead product candidate in clinical development, originating from research at Stockholm University and Karolinska Institute.
A Solution for Prediabetes Underway
Prediabetes Clinical Trials
We are currently planning our new clinical trial SHINE of our lead product candidate SiPore21®, the new and improved SiPore15®, formulated as a consumer-friendly solution for improvement in blood sugar levels in prediabetics and newly diagnosed type 2 diabetics.
Read more on our previous clinical trial STAR by clicking the link below.
A Solution for Prediabetes Underway
Prediabetes Clinical Trials
We are currently planning our new clinical trial SHINE of our lead product candidate SiPore21®, the new and improved SiPore15®, formulated as a consumer-friendly solution for improvement in blood sugar levels in prediabetics and newly diagnosed type 2 diabetics.
Read more on our previous clinical trial STAR by clicking the link below.
”All Disease Begins in the Gut
HippocratesThe Father of Medicine
RESEARCH COLLABORATIONS
